Chip stocks fall with Nvidia after data center rev disappointment
Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp. (NASDAQ:WGS), recently sold shares totaling $836,210. The transactions occurred on March 26, 2025, and involved the sale of 8,746 shares of Class A Common Stock at prices ranging from $94.4037 to $95.6577 per share. The sale comes amid a remarkable period for WGS stock, which has delivered a 933% return over the past year, despite a recent 9.6% decline in the past week.
The sales were conducted to cover tax obligations related to the vesting and settlement of restricted stock units (RSUs), according to the filing. These transactions were not discretionary but were necessary to satisfy tax withholding requirements through a "sell to cover" process.
In addition to the sales, Feeley acquired 16,250 shares of Class A Common Stock through the vesting of RSUs, which were settled for no consideration. Following these transactions, Feeley holds 15,996 shares directly.
GeneDx Holdings Corp., formerly known as Sema4 Holdings Corp., is a health services company based in Stamford, Connecticut.
In other recent news, GeneDx Holdings Corp reported impressive financial results for the fourth quarter of 2024, surpassing both earnings and revenue expectations. The company achieved an earnings per share (EPS) of $0.08, which contrasts sharply with the forecasted loss of $0.48. Revenue reached $95.3 million, exceeding the anticipated $61.7 million. This marks GeneDx’s second consecutive quarter of profitability, with adjusted net income reported at $16.8 million. Additionally, revenue from exome and genome testing grew by 101% year-over-year. The company has also launched a new Ultra Rapid Whole Genome Sequencing product, which promises faster results. GeneDx has expanded its sales team and integrated new operational strategies, aiming for significant growth in 2025 with projected revenues between $350 million and $360 million. These developments have been met with positive investor sentiment, as reflected in the company’s financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.